Menu Search
Equities

Aytu Biopharma Inc

0A8M:LSE

Aytu Biopharma Inc

Actions
  • Price (USD)3.37
  • Today's Change0.00 / 0.00%
  • Shares traded464.00
  • 1 Year change+87.22%
  • Beta--
Data delayed at least 20 minutes, as of May 15 2024 17:47 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company’s Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Company’s prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.

  • Revenue in USD (TTM)98.50m
  • Net income in USD-18.00m
  • Incorporated2015
  • Employees150.00
  • Location
    Aytu Biopharma Inc7900 E. Union Avenue, Suite 920DENVER 80237United StatesUSA
  • Phone+1 (720) 437-6580
  • Fax+1 (302) 636-5454
  • Websitehttps://aytubio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.